Drug Profile
FPFS 1169
Alternative Names: -(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride; 1-(benzofuran-2-yl)-2-propylaminopentane; Benzofuranylpropylaminopentane; BPAP-cpd; FPFS1169; R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane; R-(-)-BPAP; R-FPFS-1169Latest Information Update: 23 Jul 2014
Price :
$50
*
At a glance
- Originator Fujimoto Pharmaceutical
- Class Antiparkinsonians; Benzofurans; Neuroprotectants; Propylamines; Small molecules
- Mechanism of Action Apoptosis inhibitors; Catecholamine receptor agonists; Proto-oncogene proteins c-bcl-2 stimulants; Serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 23 Jul 2014 No development reported - Phase-II for Parkinson's disease in United Kingdom (Injection)